During this segment of the Oncology Stakeholders Summit, Spring 2015 series, Bruce Feinberg, DO; Scott Gottlieb, MD; and Michael Kolodziej, MD, discuss their concerns and the concerns of manufacturers regarding the inclusion of information on patient-reported outcomes (PROs) in drug labels.
Dr Gottlieb discusses the FDA’s role in allowing the inclusion of PRO data, notes the cumbersome process that manufacturers are faced with when incorporating the data into drug labels, and describes his concerns regarding how PRO data may be interpreted or misinterpreted by patients. For instance, he explains that in the oncology setting, where data regarding a drug’s efficacy are often the focus, if data on PROs are included in a drug label, patients may focus instead on quality-of-life claims. He adds that patients often make trade-offs based on side effect profiles.
Dr Kolodziej remarks that the costs of drugs further complicate the treatment decision-making process, especially in cancer recurrence scenarios. “I would want to know whether [the drug] works and what it is going to cost me,” says Dr Kolodziej, who is hopeful that PROs data will help to better define the true costs of healthcare.
Because patients will use the information found on drug labels when making personalized treatment decisions, Dr Kolodziej emphasizes the importance of considering PRO data as part of shared decision making.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Industry Experts Tackle Specialty Drug Access Challenges for Employer Benefit Plans
May 2nd 2024Representatives from ICON plc and Symphony Health joined forces at AXS24 to discuss the challenges of managing high-cost specialty drugs and how they influence self-funded employer benefit plan design and employee access to specialty medications.
Read More